The Wall Street Journal reports that Health Secretary Robert F. Kennedy Jr. plans to release a study connecting prenatal use of Tylenol with autism risk, alongside claims about folate deficiency as a contributing factor. The findings, expected this month from the Department of Health and Human Services, also suggest a form of folate called leucovorin could mitigate autism symptoms in some individuals. Shares of Kenvue, maker of Tylenol, fell 10% amid the speculation.

The report highlights concerns about acetaminophen, a widely used pain reliever during pregnancy, though previous studies on its effects remain inconclusive. The American College of Obstetricians and Gynecologists maintains it is safe for use under medical guidance.

Meanwhile, the article raises questions about Marin County, California’s alleged shift to reduced vaccination schedules in the early 2000s, with claims that autism rates declined there compared to national trends. However, experts dispute a causal link, attributing lower rates to factors like access to private care rather than vaccine practices.

The piece also critiques vaccine protocols, citing Bill Ackman’s call for independent reviews of childhood vaccination risks and concerns about toxic ingredients in vaccines, including aluminum and polysorbate 80. It references allegations of corporate influence and public health controversies, though these claims lack peer-reviewed validation.

The text concludes with calls for transparency in medical practices, emphasizing skepticism toward pharmaceutical companies and urging scrutiny of vaccine safety.